Develops and commercializes molecular microbiology solutions for infectious diseases. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
Average growth of 63% a year over the last 4 years. Red columns mark years that ended in a loss.
The gap is $1.3M. In times of high interest rates, a gap like that can squeeze a company.
angles, checked one by one.
The 5 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
An investor who bought at the very peak is down 97% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The net profit margin is 78% — that slice of every sale is the company’s cushion in hard quarters.
Over the last 4 years, sales grew about 63% a year on average.
Over the last 12 months, company executives reported 17 buys and 2 sells. Management buying with its own money is usually read as a good sign.
The stock trades 97% above the average analyst price target.
The share set aside for the future is small; the pace of new ideas may slow. Council score: 2/10.
Getting in and out without moving the price could prove difficult. Council score: 2/10.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.